Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of CCX354-C in rheumatoid arthritis with inadequate response to methotrexate
NL-OMON34107Phase 2Not yet recruiting
- Sponsor
- ChemoCentryx
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing CCX354-C plus methotrexate with Placebo plus methotrexate (2 arms). Primary endpoints: Incidence of adverse events, Change from baseline in DAS28-CRP at Week 12 and 5 more. Planned start Aug 2010; status: not yet recruiting.
02
Drugs
CCX354
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON34107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34107.